Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
4.6
Journals
Molecules
Special Issues
Recent Progress on Biomarkers in the Diagnosis and Prognosis of...
molecules-logo
Submit to Molecules Review for Molecules Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Recent Progress on Biomarkers in the Diagnosis and Prognosis of Cancer

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Chemical Biology".

Deadline for manuscript submissions: closed (15 January 2022) | Viewed by 6685

Special Issue Editors

Dr. Youping Deng

E-Mail Website
Guest Editor
Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii, 651 Ilalo Street, Honolulu, HI 96813, USA
Interests: bioinformatics; genomics; biomarker; systems biology; biomedical informatics; cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Yuanyuan Fu

E-Mail
Guest Editor
Bioinformatics Core Facility, University of Hawaii John A. Burns School of Medicine, Honolulu, HI 96813, USA
Interests: bioinformatics; genetics; biomarkers; clinical research; molecular biology
Dr. Fan Zhang

E-Mail Website
Guest Editor
Family Medicine and Osteopathic Manipulative Medicine, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
Interests: bioinformatics; genetics; biomarkers; clinical research; molecular biology
Special Issues, Collections and Topics in MDPI journals
Dr. Mehdi Pirooznia

E-Mail Website
Guest Editor
Bioinformatics and Computational Biology core, the National Heart Lung and Blood Institute, NIH (NHLBI/NIH), Bethesda, MD 20892, USA
Interests: bioinformatics; genetics; biomarkers; clinical research; molecular biology

Special Issue Information

Dear Colleagues,

Cancer is one of the leading causes of morbidity and mortality worldwide. It is urgent to identify, develop, and validate novel biological markers for early cancer detection and mortality risk assessment. In recent years, tremendous progress has been made in treating cancer due to the rapid development of diagnostic and prognostic biomarkers and advances in technologies driving personalized therapies. This Special Issue of “Recent Progress on Biomarkers in the Diagnosis and Prognosis of Cancer” aims to promote research on the development and validation of promising cancer biomarkers, collaborative databases, and informatics systems and new technologies or the refinement of existing technologies in order to provide up-to-date information on cancer biomarker research development for everyone involved in cancer research, risk reduction, treatment, and patient care.

Prof. Dr. Youping Deng
Dr. Yuanyuan Fu
Dr. Fan Zhang
Dr. Mehdi Pirooznia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • biomarker
  • diagnosis
  • prognosis
  • bioinformatics
  • genomics
  • clinical research
  • molecular biology
  • epidemiology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2022 KiB  
Article
Bacterial Diversity Correlates with Overall Survival in Cancers of the Head and Neck, Liver, and Stomach
by Rebecca M. Rodriguez, Mark Menor, Brenda Y. Hernandez, Youping Deng and Vedbar S. Khadka
Molecules 2021, 26(18), 5659; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26185659 - 17 Sep 2021
Cited by 7 | Viewed by 1926
Abstract
One in five cancers is attributed to infectious agents, and the extent of the impact on the initiation, progression, and disease outcomes may be underestimated. Infection-associated cancers are commonly attributed to viral, and to a lesser extent, parasitic and bacterial etiologies. There is [...] Read more.
One in five cancers is attributed to infectious agents, and the extent of the impact on the initiation, progression, and disease outcomes may be underestimated. Infection-associated cancers are commonly attributed to viral, and to a lesser extent, parasitic and bacterial etiologies. There is growing evidence that microbial community variation rather than a single agent can influence cancer development, progression, response to therapy, and outcome. We evaluated microbial sequences from a subset of infection-associated cancers—namely, head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), and stomach adenocarcinoma (STAD) from The Cancer Genome Atlas (TCGA). A total of 470 paired tumor and adjacent normal samples were analyzed. In STAD, concurrent presence of EBV and Selemonas sputigena with a high diversity index were associated with poorer survival (HR: 2.23, 95% CI 1.26–3.94, p = 0.006 and HR: 2.31, 95% CI 1.1–4.9, p = 0.03, respectively). In LIHC, lower microbial diversity was associated with poorer overall survival (HR: 2.57, 95% CI: 1.2, 5.5, p = 0.14). Bacterial within-sample diversity correlates with overall survival in infection-associated cancers in a subset of TCGA cohorts. Full article
(This article belongs to the Special Issue Recent Progress on Biomarkers in the Diagnosis and Prognosis of Cancer)
►▼ Show Figures

Figure 1

15 pages, 4126 KiB  
Article
Design, Synthesis and Biological Evaluation of Novel Pyrazolo[1,2,4]triazolopyrimidine Derivatives as Potential Anticancer Agents
by Saeb Aliwaini, Bassam Abu Thaher, Ihab Al-Masri, Nabil Shurrab, Said El-Kurdi, Dieter Schollmeyer, Basem Qeshta, Mariam Ghunaim, René Csuk, Stefan Laufer, Lars Kaiser and Hans-Peter Deigner
Molecules 2021, 26(13), 4065; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26134065 - 02 Jul 2021
Cited by 14 | Viewed by 3742
Abstract
Three novel pyrazolo-[4,3-e][1,2,4]triazolopyrimidine derivatives (1, 2, and 3) were designed, synthesized, and evaluated for their in vitro biological activity. All three compounds exhibited different levels of cytotoxicity against cervical and breast cancer cell lines. However, compound 1 [...] Read more.
Three novel pyrazolo-[4,3-e][1,2,4]triazolopyrimidine derivatives (1, 2, and 3) were designed, synthesized, and evaluated for their in vitro biological activity. All three compounds exhibited different levels of cytotoxicity against cervical and breast cancer cell lines. However, compound 1 showed the best antiproliferative activity against all tested tumor cell lines, including HCC1937 and HeLa cells, which express high levels of wild-type epidermal growth factor receptor (EGFR). Western blot analyses demonstrated that compound 1 inhibited the activation of EGFR, protein kinase B (Akt), and extracellular signal-regulated kinase (Erk)1/2 in breast and cervical cancer cells at concentrations of 7 and 11 µM, respectively. The results from docking experiments with EGFR suggested the binding of compound 1 at the ATP binding site of EGFR. Furthermore, the crystal structure of compound 3 (7-(4-bromophenyl)-9-(pyridin-4-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine) was determined by single crystal X-ray analysis. Our work represents a promising starting point for the development of a new series of compounds targeting EGFR. Full article
(This article belongs to the Special Issue Recent Progress on Biomarkers in the Diagnosis and Prognosis of Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop